6 results about "Hormone-sensitive" patented technology

The invention relates to the technical field of biology, and provides a genetic marker for children nephrotic syndrome genetic risk assessment. The invention relates to genetic detection and application of hormone sensitive nephrotic syndrome (pSSNS) of children. Nine risk sites, including new sites of 1q23.1, 1p36.13, 5p13.2, 10q21.3, 10q24.1 and the like, highly related to diseases are found by integrating whole genome association research (GWAS) data, combining Meta analysis and a conjugate false discovery rate (conjFDR) method and taking genetic information of IgA nephropathy as assistance. Research results show that genes near the loci have differential expression in pSSNS and IgAN patients, which prompts that the genes play an important role in the occurrence and development of diseases. The invention provides a molecular detection method based on the risk site, which can be used for risk assessment, auxiliary diagnosis and prognosis prediction of children's nephropathy. Meanwhile, the invention provides potential application values of the loci and related genes thereof in individualized medication and targeted therapy.

The invention belongs to the technical field of medical informatization and artificial intelligence, and particularly relates to a lupus erythematosus patient layering and personalized treatment scheme recommendation system which comprises a data access module, a data preprocessing module, a graph neural network modeling module, a layering label updating module, a subtype division module and a treatment scheme recommendation module. Accessing multi-source data through a data interface, constructing a data association graph by adopting a graph neural network, and analyzing a potential association relationship among data of different dimensions; a deep learning algorithm is combined to dynamically update layering labels of patients, the patients are subdivided into hormone sensitive subtypes, immunosuppressor dependent subtypes, refractory subtypes and other subtypes, and personalized treatment schemes are matched. According to the method, the layering accuracy of the patient and the scientificity of a treatment scheme can be improved, the dependence on artificial experience is reduced, and technical support is provided for precise medical treatment of the lupus erythematosus patient.

This invention relates to the field of biomedical technology and proposes a biomarker for reflecting the efficacy of hormone therapy for allergic rhinitis and its application. The biomarker includes one or more combinations of IFNGR1, Furin, and CSF1R. The biomarkers IFNGR1, Furin, and CSF1R of this invention can all differentiate between hormone-sensitive and hormone-insensitive rhinitis. Their expression levels in the nasal secretions of patients with hormone-insensitive allergic rhinitis are significantly lower than those of patients with hormone-sensitive allergic rhinitis, thus reflecting the efficacy of hormone therapy for allergic rhinitis. Furthermore, compared with a single biomarker, the combination of the three biomarkers has better discriminative ability and better efficacy, providing important evidence for subsequent treatment of allergic rhinitis.

The invention relates to the technical field of data processing, in particular to a system and a method for auxiliary analysis of hormone-sensitive chronic cough, and the method comprises the following steps: collecting target indexes of a patient, including allergic disease history, sour regurgitation heartburn symptom, hematophilic granulocyte count, CRP, IgE, FEV1 / FVC and FeNO; preprocessing the target index to obtain a preprocessed index; and generating a risk score corresponding to the hormone-sensitive chronic cough according to the pretreatment index. In order to solve the problems that in the prior art, hormone-sensitive cough diagnosis indexes need to depend on a complex detection instrument to be collected, and implementation is difficult, on the basis of regression analysis, the indexes of auxiliary analysis are determined to be clinical data which can be obtained easily based on clinical symptoms, blood routine indexes, lung function examination and the like of a patient, and the hormone-sensitive cough diagnosis indexes are obtained. And a related auxiliary analysis system is established, so that complex instruments required in the traditional medical examination process are omitted, and the medical examination process can be quickly completed in any level of medical institutions.

This invention relates to the field of biomedical technology and proposes RBP4 and Ferritin as biomarkers for evaluating the efficacy of hormone therapy for allergic rhinitis. The biomarkers include one or a combination of RBP4 and Ferritin. Studies have confirmed that both RBP4 and Ferritin are capable of distinguishing between hormone-sensitive and hormone-insensitive allergic rhinitis. RBP4 is expressed at higher levels in the hormone-sensitive allergic rhinitis group, while Ferritin is expressed at higher levels in the hormone-insensitive allergic rhinitis group. Compared to single biomarker detection, the combined use of RBP4 and Ferritin significantly improves the differential diagnostic efficacy, providing better differentiation between the two patient groups.

This invention relates to the field of biomedical technology and proposes a biomarker for evaluating the efficacy of hormone therapy for allergic rhinitis and its application. The biomarker includes one or a combination of TFF3 and WFDC2. Both TFF3 and WFDC2 can differentiate between hormone-sensitive and hormone-insensitive rhinitis. Compared to a single biomarker, the combined use of the two significantly improves the differentiation efficacy and provides better differentiation between the two types of patients.